David A Pattison
David A Pattison
Associate Professor (UQ); Deputy Director, Department of Nuclear Medicine, RBWH
Verified email at health.qld.gov.au
Title
Cited by
Cited by
Year
68 Ga-DOTATATE and 18 F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity
CA Chang, DA Pattison, RW Tothill, G Kong, TJ Akhurst, RJ Hicks, ...
Cancer Imaging 16 (1), 1-12, 2016
972016
Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma
G Kong, S Grozinsky-Glasberg, MS Hofman, J Callahan, A Meirovitz, ...
The Journal of Clinical Endocrinology & Metabolism 102 (9), 3278-3287, 2017
702017
Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration …
J Violet, S Sandhu, A Iravani, J Ferdinandus, SP Thang, G Kong, ...
Journal of Nuclear Medicine 61 (6), 857-865, 2020
562020
Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non‐metastatic prostate cancer: implementation of standardized management guidelines
AS Cheung, D Pattison, I Bretherton, R Hoermann, D Lim Joon, E Ho, ...
Andrology 1 (4), 583-589, 2013
472013
TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC …
MS Hofman, L Emmett, SK Sandhu, A Iravani, AM Joshua, JC Goh, ...
Journal of Clinical Oncology 38 (15_suppl), 5500-5500, 2020
412020
High clinical and morphologic response using 90 Y-DOTA-octreotate sequenced with 177 Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky …
G Kong, J Callahan, MS Hofman, DA Pattison, T Akhurst, M Michael, P Eu, ...
European journal of nuclear medicine and molecular imaging 44 (3), 476-489, 2017
342017
64Cu-SARTATE PET imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor …
RJ Hicks, P Jackson, G Kong, RE Ware, MS Hofman, DA Pattison, ...
Journal of Nuclear Medicine 60 (6), 777-785, 2019
312019
Molecular imaging in the investigation of hypoglycaemic syndromes and their management
DA Pattison, RJ Hicks
Endocrine-related cancer 24 (6), R203-R221, 2017
242017
Quantitative assessment of thyroid-to-background ratio improves the interobserver reliability of technetium-99m sestamibi thyroid scintigraphy for investigation of amiodarone …
DA Pattison, J Westcott, M Lichtenstein, HB Toh, D Gunawardana, ...
Nuclear medicine communications 36 (4), 356-362, 2015
232015
Intermittent severe, symptomatic hyponatraemia due to the nephrogenic syndrome of inappropriate antidiuresis
S Soule, C Florkowski, H Potter, D Pattison, M Swan, P Hunt, P George
Annals of clinical biochemistry 45 (5), 520-523, 2008
232008
Strongyloidiasis in personnel of the Regional Assistance Mission to Solomon Islands (RAMSI)
DA Pattison, R Speare
Medical journal of Australia 189 (4), 203-206, 2008
232008
Role of fluorodeoxyglucose PET/computed tomography in targeted radionuclide therapy for endocrine malignancies
DA Pattison, MS Hofman
PET clinics 10 (4), 461-476, 2015
182015
18F-FDG–avid thyroid incidentalomas: the importance of contextual interpretation
DA Pattison, M Bozin, A Gorelik, MS Hofman, RJ Hicks, A Skandarajah
Journal of Nuclear Medicine 59 (5), 749-755, 2018
172018
Amiodarone-induced destructive thyroiditis associated with coronary artery vasospasm and recurrent ventricular fibrillation
MJ Brooks, DA Pattison, EP Teo, S Price, R Gurvitch
European thyroid journal 2 (1), 65-67, 2013
152013
Enhanced white adipose tissue metabolism in iatrogenic Cushing's syndrome with FDG PET/CT
DA Pattison, MS Hofman, E Lau, R Ware, RJ Hicks
The Journal of Clinical Endocrinology & Metabolism 99 (9), 3041-3042, 2014
112014
Diagnostic challenges in a patient with an occult insulinoma: 68 Ga‐DOTA‐exendin‐4 PET/CT and 68Ga‐DOTATATE PET/CT
E Bongetti, MH Lee, DA Pattison, RJ Hicks, R Norris, N Sachithanandan, ...
Clinical case reports 6 (4), 719, 2018
102018
A new theranostic paradigm for advanced thyroid cancer
DA Pattison, B Solomon, RJ Hicks
Journal of Nuclear Medicine 57 (10), 1493-1494, 2016
92016
[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ...
The Lancet 397 (10276), 797-804, 2021
82021
Mitogen-activated protein kinase pathway inhibition for Redifferentiation of radioiodine refractory differentiated thyroid Cancer: an evolving protocol
A Iravani, B Solomon, DA Pattison, P Jackson, A Ravi Kumar, G Kong, ...
Thyroid 29 (11), 1634-1645, 2019
82019
15th international thyroid congress program and meeting abstracts
RN Miguel, J Sanders, J Furmaniak, BR Smith, C Li, F Menconi, R Osman, ...
Thyroid 25 (S1), P-1-A-337, 2015
82015
The system can't perform the operation now. Try again later.
Articles 1–20